キャリアアドバイザーが教える! 職種別レジメの書き方

英文のレジメサンプル 2

CURRICULUM VITAE

【PROFILE】

TARO YAMADA
Address: 2-14-6 LXS Tsukiji1303 Tsukiji,Cyuou-ku,Tokyo 104-0045
Tel:03-6278-8721  Fax: 03-6278-8748
Email: taro.yamada@bbc.com
Mobile: 090xxxxxxxxx

【SUMMARY】

After getting a Master of Science Degree (M.S.) in Medical Sciences from Tokyu University, joined Pharma Japan Co., Ltd.--currently Pharam Internaitonal.
I researched the effects and stability of various medicines in the Analytical Science Section of the Pharmaceutical Development Dept.
I transfered to the PMS Division, where I was in charge of domestic and foreign reports concerning adverse drug reactions.
Subsequently, I joined ABC Pharma. Ltd., where I worked in the PMS Division.

【Resume】

After graduating from Department of Hygienic Pharmacy, Tokyu University of Pharmacy, I joined ABC Pharmaceutical Co., Ltd. Assigned to Clinical Development Department, I consistently worked as a monitor in charge of Phase II to Phase III for new drugs. As the company had adopted a project system, I experienced various assignments from protocol planning to CRF preparation, DM, preparation of submission summary, overview report and publication papers, though under the old GCP. After introduction of the new GCP, I worked as a monitor in the cardiovascular surgery field for 2 years. Subsequently, I moved to the unit responsible for the overall management of basic and clinical studies. For 1 year and 3 months, I served as an assistant to the project leader. The drug I was dealing with had been introduced from an American venture company, and therefore, I have acquired the experience of negotiating in English. After the management department and clinical development department were merged, I again worked as a monitor for infective area under the new GCP. At present, I am engaged in planning a Phase I study for an antidiabetic drug.

【Position desired】

Clinical development staff member in a pharmaceutical company

【Professional Career】

April 199X-
Joined ABC Pharmaceutical Co., Ltd. Assigned to Clinical Development Department, Development Division, and worked as monitor for new drugs. Drugs and studies handled after the end of training period:

  • Extension of indications of Palux, a joint development project with the former Green Cross Corporation: Monitoring, planning, CRF preparation and DM for spinal canal stenosis (early Phase II), and contrast radiography for superior mesenteric artery (Phase III) Engaged in preparation of the submission dossier for Palux in contrast radiography of superior mesenteric artery, which was approved by the government (Development of spinal canal stenosis was discontinued.)
  • AS-013 (Palux prodrug), a joint project with the former Green Cross Corporation: Monitoring, planning, CRF preparation and DM for chronic arterial obstruction (early Phase II) and collagenosis (Taisho Pharmaceutical withdrew from this project, and Green Cross continued the development.)
  • TTC-909, a joint project with Teijin: Monitoring for chronic arterial obstruction (Phase III)

March 199x-
Nominated for a position in charge of development of new gastrointestinal drugs

  • IT-066 (late Phase II, Phase III)
    Monitoring, planning, CRF preparation and DM for gastric ulcer and duodenal ulcer (applied but not approved)
  • Clarith (early Phase II)
    Monitoring for eradication of Helicobacter pylori (concurrent use of two drugs) (The regimen of concurrently using 3 drugs was adopted by the medical society, and this development project was cancelled.)

October 199x-

  • TTC-909, a joint development project with Teijin Monitoring under the new GCP for chronic arterial obstruction (Phase III) (In Phase III, a significant difference from placebo could not be demonstrated, and therefore, submission was given up.)

January 200x-
Transferred to Development Promotion Department (responsible for total management of basic and clinical studies)

  • INS-1 (anti-diabetic)
    Management of the project, in which negotiations with an American venture company were handled, by attending meetings and preparing documents in English

August 200x-
Merger of clinical development department and development promotion department

  • ABT-773, a joint project with Dynabbott:
    Monitoring under the new GCP for community acquired pneumonia (Phase IIa)
    The cost of the drug substance could not be reduced, and the clinical study was temporarily suspended.

April 200x-
TS-021

Preparation of PRT, the investigator's brochure and informed consent form, and negotiation for manufacture of the study drug.

【ACADEMIC RECORD】

March 1989
Graduated from Regular Course, Hyogo Prefectural Hakuyo Senior High School

April 1989
Entered Hygienic Pharmacy Department, Tokyu University of Pharma

April 1993
Graduated from Hygienic Pharmacy Department, Hoshi College of Pharmacy

【Qualifications】

April 1993
Passed National Examination for Pharmacist and obtained license to practice pharmacy

【OTHER】

Birth date:June 15, 1973
Hobbies:skiing, skating, watching sport games

【Self PR】

I have been engaged in clinical studies for new drugs for the past 10 years. Although I mostly worked for vascular surgery, I have experienced other various fields from the time before the new GCP. I am therefore confident that I will be able to deal with any areas. As I also served as an assistant for the total management of basic and clinical studies, though only for a short 1 year & 3 month-period, I am able to grasp clinical studies from broad perspectives. During the time, I negotiated with the American venture company, attending meetings, sending E-mails and preparing documents in English. Meanwhile, I attended in-house training sessions for medical English (10-day residential course) and English business writing. TOEIC 750 points may not yet be sufficient for business operations in English, but I am studying hard every day. Since I have experienced almost all the stages of clinical development, I will be able to try my best in whatever position I will get.

職業別レジメサンプル一覧に戻る 未経験者が応募可能な案件も多数! 会員登録はこちら
転職相談いたします 03-6278-8721

転職活動に役立つ! 転職サポートツール